A systematic review of miRNAs as biomarkers for chemotherapy-induced cardiotoxicity in breast cancer patients reveals potentially clinically informative panels as well as key challenges in miRNA research

Cameron Brown1, Michael Mantzaris2, Elpiniki Nicolaou1, Georgia Karanasiou3, Elisavet Papageorgiou3, Giuseppe Curigliano4, Daniela Cardinali4, Gerasimos Filippatos5, Nikolaos Memos5, Katerina K. Naka6, Andri Papakostantinou7, Paris Vogazianos1, Erietta Ioulianou1, Christos Shammas1, Anastasia Constantinidou3, Federica Tozzi1, Dimitrios I. Fotiadis2 and Athos Antoniades1*

Abstract
Breast cancer patients are at a particularly high risk of cardiotoxicity from chemotherapy having a detrimental effect on quality-of-life parameters and increasing the risk of mortality. Prognostic biomarkers would allow the management of therapies to mitigate the risks of cardiotoxicity in vulnerable patients and a key potential candidate for such biomarkers are microRNAs (miRNA). miRNAs are post-transcriptional regulators of gene expression which can also be released into the circulatory system and have been associated with the progression of many chronic diseases including many types of cancer. In this review, the evidence for the potential application of miRNAs as biomarkers for chemotherapy-induced cardiotoxicity (CIC) in breast cancer patients is evaluated and a simple meta-analysis is performed to confirm the replication status of each reported miRNA. Further selection of miRNAs is performed by reviewing the reported associations of each miRNA with other cardiovascular conditions. Based on this research, the most representative panels targeting specific chemotherapy agents and treatment regimens are suggested, that contain several informative miRNAs, including both general markers of cardiac damage as well as those for the specific cancer treatments.

Keywords: miRNA, microRNA, Cardiotoxicity, Breast cancer, Chemotherapy, Anthracycline

Introduction
Cardiomyopathies and cardiovascular diseases are well-known side effects of the principle chemotherapy agents used against breast cancer (BC) such as anthracyclines, monoclonal antibodies, alkylating agents and anti-metabolites [1, 2]. As cancer treatment outcomes are improving, progressive cardiac dysfunctions can impact post-treatment survival times [3, 4] to the extent that, following chemotherapy treatment, the risk of death is doubled compared to non-cancer sufferers and this figure is expected to continue increasing with time [4]. There are several established cardiotoxicity risk factors, such as the type of chemotherapy agent, the cumulative dosage and the infusion regime, in addition to patient-related factors such as age, female sex and any pre-existing cardiac

*Correspondence: athos.antoniades@stremble.com
1 Stremble Ventures Ltd, 59 Christaki Kranou, 4042 Limassol, Cyprus
Full list of author information is available at the end of the article
or cardiovascular conditions [5]. BC patients are at considerable risk of chemotherapy-induced cardiotoxicity (CIC) through the use of agents such as anthracyclines and HER2-directed monoclonal antibodies although this could be reduced if identified and managed from the outset of treatment [6]. Anthracycline-associated cardiotoxicity can cause injury and death of cardiomyocytes leading to Left Ventricular Dysfunction (LVD) which produces symptoms consistent with heart failure and is often irreversible [7]. Biomarkers of cardiotoxicity include cardiac troponins I and T (cTnI, cTnT), which are released through myocyte necrosis and the N-terminal prohormone of brain natriuretic peptide (NT-proBNP) which is linked to cardiac strain [8]. Elevated levels of these biomarkers have been noted in cardiovascular conditions including cardiotoxicity but require establishing baseline values and repeated measurements [9]. The monitoring of such biomarkers in an oncology setting has not been widely adopted although it is recommended for the management of cancer patients and to initiate cardioprotective treatments where required [10].

Cardiotoxicity is the result of a series of complex reactions to a chemical agent involving mechanisms such as metabolic disorders, oxidative stress, mitochondrial dysfunction, calcium overload, myocardial fibrosis and cardiomyocyte autophagy [11, 12]. Over 200 genes have been identified within the pathway of anthracycline metabolism and transport including several genetic variations affecting cardiotoxicity risk [13]. However, the dynamics of the relationships between chemotherapy treatments and cardiotoxicity pathways are highly complex and the significance of some of these genetic variations are still largely unknown [11]. Changes in gene expression can be regulated by several types of non-coding RNA (ncRNA) consisting of long-non coding RNA (lncRNA), circular RNA (circRNA) and microRNA (miRNA) [14]. miRNAs are short (17–24 nucleotide) RNA sequences which act as modifiers of gene expression by preferentially binding to messenger RNA (mRNA) transcripts either in the 3′-untranslated region (UTR) or coding sequence, leading to inhibition of mRNA translation, protein synthesis and promoting mRNA degradation [15]. Binding of miRNAs to functional mRNA transcripts can be imprecise, involving seed sequences of only 6–8 nucleotides [16] meaning that each miRNA can have multiple mRNA targets, potentially influencing several genes and functional pathways [17]. There are over 2000 miRNAs identified so far in humans and a nomenclature of numbers and letters prefixed with “miR” has been established based primarily on order of discovery and orthologs in other species [18]. In the cell cytoplasm, miRNAs go through a process of maturation with the Dicer RNAse III endonuclease enzyme which lead to subtle differences in their RNA sequences leading to groups of very similar miRNAs, termed families, which may or may not have similar or overlapping functions and mRNA targets [16]. Identical mature miRNAs can also originate from different areas of the genome, for example, miR-7-1 (chromosome 9) and miR-7-2 (chromosome 15). miRNAs can be further classified into isomirs which are changes in sequence length or nucleotides at the 3′ or 5′ ends, sometimes with modifications to function and targets [19].

Whilst miRNAs are active within the cytoplasm, they can also be secreted into vesicles (exosomes), bound to proteins or lipids and enter the circulatory system where they may potentially facilitate cellular communications [20]. As indicated in Fig. 1, many types of cell within the cardiovascular system including cardiomyocytes, fibroblasts, vascular smooth muscle cells and endothelial cells can release exosomes containing microRNAs [21]. Moreover, several types of blood cells including erythrocytes, platelets, leukocytes and megakaryocytes can also release miRNAs [22, 23] which makes the analysis of blood samples problematic unless prepared carefully [24]. As dysregulation of miRNAs has already been associated with many severe diseases [25], these extracellular miRNAs are of great interest as biomarkers due to their properties of being potentially disease-specific, stable, quantifiable and easily extracted from a range of clinical samples [26]. In this manuscript we review the potential of microRNAs (miRNAs) as biomarkers for chemotherapy-induced cardiotoxicity in BC patients.

Methods

A systematic literature review was carried out using the PRISMA methodology [27]. The databases of PubMed, Cochrane Central, Embase, Scopus and Google Scholar were systematically searched with the terms ‘chemotherapy induced cardiotoxicity’, ‘breast cancer’, ‘biomarkers’, ‘microRNA’, ‘anthracycline’, ‘trastuzumab’, ‘doxorubicin’ and ‘epirubicin’. The search was restricted to articles in English between the years of 2000–2022 and only considered miRNAs linked to cardiotoxicity in clinical studies of breast cancer patients. Review papers, letters and editorial articles as well as studies in animal models and stem cells were excluded. This search resulted in 922 papers of which 166 were considered relevant and were studied at the abstract level by two authors (CB, AA). From these articles, eight were examined in full and selected for inclusion in this manuscript.

In order to further clarify the function of each of the miRNAs shortlisted by the review in other cardiovascular conditions, the literature was further searched for human clinical studies on each individual miRNA qualified by the terms ‘mir’, [‘miR number’], ‘microRNA’, ‘cardio’, ‘coronary’, ‘heart’, ‘human’. This review of miRNA
functions was limited to only clinical studies in cardiovascular diseases, where a significant change in expression of the relevant miRNA was reported. A total of 656 potentially relevant publications were screened and from these, 143 were selected based on their relevance. These titles were studied at the abstract level by two authors (CB, AA) and the papers selected were examined in full by both authors. Review papers, letters and editorial articles as well as studies in animal models and stem cells were excluded. A total of 104 articles were studied in full and from these, 90 were selected for inclusion.

Figure 2 shows the PRISMA diagram for the literature review as a whole with 1578 papers being identified, from which 309 were shortlisted and 112 reviewed in full. Based on the criteria outlined above, 98 papers were selected for inclusion in this manuscript.

Results
Clinical studies of breast cancer patients indicate that dysregulation of several miRNAs have been noted following anthracycline treatment [28–35], as summarised in Table 1. Many of the miRNAs examined were related to functions associated with cardiac damage such as apoptosis, hypertrophy and inflammatory responses which suggests that they could be used as potential biomarkers for the incidence of anthracycline induced cardiotoxicity. Table 1 is divided into four sections based on the strength of evidence for changes in expression in breast cancer
patients after chemotherapy. Section A includes miRNAs which have been reported statistically significant in only one study, Section B includes miRNAs which have been reported statistically significant and replicated in other studies whether significant or not. Section C includes miRNAs which have been reported as statistically non-significant and in Section D those miRNAs are reported which although were found to have statistically significant findings, they also showed contradictory expression change directions in independent studies.

The evidence from Table 1 indicates that of the 33 miRNAs investigated in these clinical studies, only 14 can be considered as potentially informative for study of cardiotoxicity as they have some indication of a significant change in expression and no contradictory results in replicated studies (Table 1, Sections A and B). The remaining 19 miRNAs have either no evidence of significant expression changes in cardiotoxicity or contradictory evidence of the direction of the expression change and were not considered further.

Within all the clinical studies reviewed, the number of patients diagnosed with cardiotoxicity was low, reaching a maximum of 20 patients. As shown in Table 2, the identification of cardiotoxicity was predominantly based on reductions in left ventricular ejection fraction (LVEF) during or after chemotherapy based on echocardiograms, which conforms to the European Society of Cardiology diagnostic methodology for identifying cardiotoxicity [5]. Other indicators of cardiotoxicity such as heart failure and acute coronary syndrome were rare, whereas, fatal arrhythmias were more common but identified in only one study. The use of cardiac Troponin levels to establish cardiotoxicity was used by one study (Table 2). Exclusion criteria for patients in all the studies included a prior history of cardiovascular events such as coronary heart disease, myocardial infarction and heart failure as well as metastatic breast cancer, severe hepatic or renal dysfunction and pregnancy. Three studies included prior chemotherapy or radiotherapy as an exclusion criterion, however, no study provided information for exposure to radiation therapies prior to or during the study period.

The pool of informative markers (Table 1, section A and B) was investigated individually in the literature to identify significant changes in expression linked to other
### Table 1
List of microRNA’s targeted by studies of breast cancer patients displaying cardiotoxicity following treatment with Anthracyclines and comparison of expression with control groups

| MicroRNA          | Reference | Subjects (Healthy Controls/Chemotherapy group) | Treatment | Period Tested | Expression Change to Control group | Differential Expression | Proposed Role                                      |
|-------------------|-----------|-----------------------------------------------|-----------|---------------|-------------------------------------|--------------------------|---------------------------------------------------|
| **Section A**     |           |                                               |           |               |                                     |                          |                                                   |
| hsa-miR-29a-3p    | [33]      | 17/17                                         | DOX       | 6 months      | Increased                           | + 5 RE                   | Cardiac repair                                    |
| hsa-miR-199a-3p   | [28]      | 38/7                                          | NAC       | 2 cycles      | Increased                           | + 1.2 FC                 | Cardiomyocyte regeneration                       |
| hsa-miR-1273 g-3p | [34]      | 20/20                                         | PT        | Decreased     | −0.52Log₂ΔCt                       | Regulatory function of TGF-β pathway |
| hsa-miR-4638-3p   | [34]      | 20/20                                         | PT        | Decreased     | −1.37 Log₂ΔCt                      | Regulatory function of TGF-β pathway |
| **Section B**     |           |                                               |           |               |                                     |                          |                                                   |
| hsa-miR-34a-5p    | [33]      | 17/17                                         | DOX       | 6 months      | Increased                           | + 40 RE                  | Cardiac repair                                    |
|                   | [28]      | 38/7                                          | NAC       | 2 cycles      | Increased                           | + 24.3 FC                |                                                   |
|                   | [32]      | 44/12                                         | DOX       | 3 months      | No significant change               | –                        |                                                   |
|                   | [32]      | 14/18                                         | EPI       | 3 months      | No significant change               | –                        |                                                   |
| hsa-miR-1         | [31]      | 46/10                                         | DOX       | 4 cycles      | Increased                           | + 2Log₂FC               | Cardiac hypertrophy                              |
|                   | [28]      | 38/7                                          | NAC       | 3 months      | No significant change               | –                        |                                                   |
|                   | [32]      | 44/12                                         | DOX       | 3 months      | No significant change               | –                        |                                                   |
|                   | [32]      | 14/18                                         | EPI       | 3 months      | No significant change               | –                        |                                                   |
| hsa-miR-17-5p     | [29]      | 170/9                                         | EC-D      | 8 cycles      | No significant change               | –                        | Pro-angiogenic                                    |
|                   | [30]      | 346/19                                        | EC-D      | 8 cycles      | Decreased                           | 0.213 OR                 |                                                   |
| hsa-miR-19a       | [29]      | 170/9                                         | EC-D      | 8 cycles      | Increased                           | + 2.1 RE                 | Pro-angiogenic                                    |
|                   | [30]      | 346/19                                        | EC-D      | 8 cycles      | No significant change               | –                        |                                                   |
| hsa-miR-122-5p    | [32]      | 44/12                                         | DOX       | 3 months      | Increased                           | + 3 ΔΔCt                 | Coronary disease                                  |
|                   | [32]      | 14/18                                         | EPI       | 3 months      | No significant change               | –                        |                                                   |
| hsa-miR-130a      | [29]      | 170/9                                         | EC-D      | 8 cycles      | No significant change               | –                        | Cardiomyopathy                                    |
|                   | [30]      | 346/19                                        | EC-D      | 8 cycles      | No significant change               | –                        |                                                   |
| hsa-miR-378       | [35]      | 60/12                                         | EC-D + T  | 15 months     | Increased                           | + 4 RE                   | Pro-angiogenic                                    |
| hsa-miR-423       | [29]      | 170/9                                         | EC-D      | 8 cycles      | No significant change               | –                        |                                                   |
| hsa-miR-499       | [31]      | 46/10                                         | DOX       | 4 cycles      | No significant change               | –                        |                                                   |
|                   | [33]      | 17/17                                         | DOX       | 6 months      | Increased                           | + 6.5 RE                 | Acute myocardial infarction                      |
|                   | [32]      | 44/12                                         | DOX       | 3 months      | Increased                           | + 2 ΔΔCt                 |                                                   |
|                   | [32]      | 14/18                                         | EPI       | 3 months      | No significant change               | –                        |                                                   |
|                   | [33]      | 17/17                                         | DOX       | 6 months      | Increased                           | + 15 RE                  |                                                   |
| MicroRNA | Reference | Subjects (Healthy Controls/Chemotherapy group) | Treatment | Period Tested | Expression Change to Control group | Differential Expression | Proposed Role |
|----------|-----------|-----------------------------------------------|-----------|---------------|-----------------------------------|------------------------|---------------|
| hsa-miR-885-5p | [32] | 44/12 | DOX | 3 months | Increased | + 2 ΔΔCt | Liver toxicity |
|          | [32] | 14/18 | EPI | 3 months | No significant change | – | |
| Section C | hsa-Let-7b | [29] | 170/9 | EC-D | 8 cycles | No significant change | – | Pro-angiogenic |
|          |          | [30] | 346/19 | EC-D | 8 cycles | No significant change | – | |
|          | hsa-miR-17-3p | [29] | 170/9 | EC-D | 8 cycles | No significant change | – | Cardiac hypertrophy |
|          |          | [30] | 346/19 | EC-D | 8 cycles | No significant change | – | |
|          | hsa-miR-18a | [29] | 170/9 | EC-D | 8 cycles | No significant change | – | Oncogenic inhibitor |
|          |          | [30] | 346/19 | EC-D | 8 cycles | No significant change | – | in breast cancer |
|          | hsa-miR-19b-1 | [29] | 170/9 | EC-D | 8 cycles | No significant change | – | Inflammatory response |
|          |          | [30] | 346/19 | EC-D | 8 cycles | No significant change | – | |
|          | hsa-miR-92a | [29] | 170/9 | EC-D | 8 cycles | No significant change | – | Pro-angiogenic |
|          |          | [30] | 346/19 | EC-D | 8 cycles | No significant change | – | |
|          | hsa-miR-133a | [28] | 38/7 | NAC | 3 months | No significant change | – | Acute myocardial infarction |
|          | hsa-miR-133b | [31] | 46/10 | DOX | 4 cycles | No significant change | – | Acute myocardial infarction |
|          |          | [28] | 38/7 | NAC | 3 months | No significant change | – | |
|          | hsa-miR-146a | [31] | 46/10 | DOX | 4 cycles | No significant change | – | Inflammatory response |
|          | hsa-miR-208a | [28] | 38/7 | NAC | 3 months | No significant change | – | Cardiomyocyte damage |
|          |          | [31] | 46/10 | DOX | 4 cycles | No significant change | – | |
|          | hsa-miR-208b | [28] | 38/7 | NAC | 3 months | No significant change | – | Cardiomyocyte damage |
|          |          | [31] | 46/10 | DOX | 4 cycles | No significant change | – | |
|          | hsa-miR-296 | [29] | 170/9 | EC-D | 8 cycles | No significant change | – | Angiogenesis |
|          |          | [30] | 346/19 | EC-D | 8 cycles | No significant change | – | |
| Section D | hsa-miR-20a | [29] | 170/9 | EC-D | 8 cycles | Increased | +1.1 RE | Pro-angiogenic |
|          |          | [30] | 346/19 | EC-D | 8 cycles | Decreased | 0.264 OR | |
|          | hsa-Let-7f | [29] | 170/9 | EC-D | 8 cycles | Increased | +1.1 RE | Pro-angiogenic |
|          |          | [30] | 346/19 | EC-D | 8 cycles | Decreased | 0.228 OR | |
cardiovascular diseases and are discussed in detail below and summarised in Table 3. A total of 90 relevant studies were identified reporting significant expression changes in these specific miRNAs. Several miRNAs were associated with a wide variety of cardiovascular conditions and have been studied extensively often with a broad agreement in expression direction. Where differences occur, they may be related to the disease or to the methodology employed, for example, some studies report miRNA expression from tissue samples rather than blood plasma which are known to often diverge. Three miRNAs (miR-885, 1273 and 4638) were not associated with any cardiovascular conditions in the literature to date and, therefore, they were not considered suitable for the final panel of informative miRNAs (Fig. 3).

**Table 1** Characterisation of cardiotoxicity in breast cancer patients during or after chemotherapy for each of the reviewed studies

| MicroRNA | Reference | Subjects (Healthy Controls/Chemotherapy group) | Treatment | Period | Expression Change to Control group | Differential Expression | Proposed Role |
|----------|-----------|-----------------------------------------------|-----------|--------|------------------------------------|------------------------|--------------|
| hsa-miR-126 | [29] | 170/9 | EC-D | 8 cycles | Increased | + 1.5 RE | Pro-angiogenic |
|          | [33] | 17/17 | DOX | 6 months | Increased | + 28 RE |                   |
|          | [30] | 346/19 | EC-D | 8 cycles | Decreased | 0.358 OR |                   |
| hsa-miR-210 | [29] | 170/9 | EC-D | 8 cycles | Increased | + 1.2 RE | Pro-angiogenic |
|          | [30] | 346/19 | EC-D | 8 cycles | Decreased | 0.475 OR |                   |

Table 2: microRNAs with significant changes in expression with no independent replication, Part B: microRNAs with significant changes in expression and independent replication (whether significant or not), Part C: microRNAs with no significant changes in expression detected, Part D: microRNAs with contradictory evidence of direction of expression change in independent replication. Key: EC-D = Epirubicin + Cyclophosphamide (4 cycles) followed by Docetaxel (4 cycles), DOX = Doxorubicin, EPI = Epirubicin, NAC = Cyclophosphamide + Epirubicin (4 cycles) followed by Paclitaxel (9 to 12 weeks), AC = Anthracycline chemotherapy (not specified), PT = Post-treatment, RE = Relative Expression, FC = Fold Change, OR = Odds Ratio

| Reference | Cohort size | Treatment regime | Heart failure | Acute coronary syndrome | Fatal arrhythmias | Decline of LVEF ≥10% of baseline or below 53% | Elevated Troponin level |
|-----------|-------------|------------------|---------------|------------------------|-------------------|---------------------------------------------|--------------------------|
| [28]      | 45          | NAC              | 1             | 0                      | 0                 | 17/20                                       | 0/12/18                  |
| [29]      | 179         | ECD              | 0             | 0                      | 0                 | 0/12/0                                      | 0/12/0                   |
| [30]      | 363         | ECD              | 0             | 0                      | 0                 | 0/12/0                                      | 0/12/0                   |
| [31]      | 56          | DOX              | 0             | 0                      | 0                 | 0/12/0                                      | 0/12/0                   |
| [32]      | 56/32       | EPI/DOX          | 0             | 0                      | 0                 | 0/12/0                                      | 0/12/0                   |
| [33]      | 34          | DOX              | 0             | 0                      | 0                 | 0/12/0                                      | 0/12/0                   |
| [34]      | 40          | AC               | 0             | 0                      | 0                 | 0/12/0                                      | 0/12/0                   |
| [35]      | 72          | ECD-T            | 0             | 0                      | 0                 | 0/12/0                                      | 0/12/0                   |

Part A: many genes such as the heat shock protein 60 (HSP60), Kruppel-like factor 4 (KLF4), Cyclin-dependent kinase-9 (CdK9), histone deacetylase 4 (HDAC4), SRY-Box transcription factor (SOX6), Frizzled class receptor (FZD7) and fibroblast growth factor receptor substrate 2 (FRS2) [124, 125]. In addition, it is connected with many transcription factors including; myocardin, Nkx2.5, serum response factor (SRF), Wnt pathway, fibroblast growth factor (FGF) pathway and Heart and Neural Crest Derivatives Expressed 2 (HAND2) [124, 125]. miR-1 influences the inflammatory cytokine response through modulating KLF4 and NF-κB pathways as well as the TGF-β signalling pathway. miR-1 has been associated with a variety of cardiovascular conditions including: acute myocardial infarction [36–41], sudden cardiac death [42], microvascular obstruction leading to failed myocardial reperfusion [43], acute viral myocarditis [44], hypertrophic cardiomyopathy [45, 46], idiopathic dilated cardiomyopathy [47], hypertrophic obstructive cardiomyopathy patients undergoing trans-coronary ablation of septal...
Table 3  Supporting evidence for the informative microRNA's from clinical studies of cardiovascular disorders, indicating the sample type, methodology, cardiovascular condition and the direction of miRNA expression

| miRNA       | Reference | Sample Type                  | Evaluation Method | Cardiovascular condition                  | Expression Change to controls |
|-------------|-----------|------------------------------|-------------------|-------------------------------------------|------------------------------|
| miR-1-3p    | [36]      | Plasma                       | qPCR              | Acute myocardial infarction               | Increased                    |
|             | [37]      | Serum + urine                | qPCR              | Acute myocardial infarction               | Increased                    |
|             | [38]      | Plasma                       | qPCR              | Acute myocardial infarction               | Increased                    |
|             | [39]      | Plasma                       | NGS               | Acute myocardial infarction               | Increased                    |
|             | [40]      | Plasma                       | qPCR              | Acute myocardial infarction               | Increased                    |
|             | [41]      | Plasma                       | qPCR              | Acute myocardial infarction               | Increased                    |
|             | [42]      | FFPE myocardial tissue       | qPCR              | Sudden cardiac death                      | Increased                    |
|             | [43]      | Plasma                       | NGS + qPCR        | Failed myocardial reperfusion             | Increased                    |
|             | [44]      | PBMC                         | qPCR              | Acute viral myocarditis                   | Increased                    |
|             | [45]      | Plasma                       | qPCR              | Hypertrophic cardiomyopathy               | Increased                    |
|             | [46]      | Cardiac tissue               | qPCR              | Hypertrophic cardiomyopathy               | Decreased                    |
|             | [47]      | Endomyocardial biopsies      | qPCR + microarray | Dilated cardiomyopathies                  | Increased                    |
|             | [48]      | Serum                        | qPCR              | Transcoronal ablation of septal hypertrophy (TASH) | Increased | |
|             | [49]      | Myocardial tissue            | NGS               | Tetralogy of Fallot                       | Decreased                    |
|             | [50]      | Plasma                       | qPCR              | Takotsubo cardiomyopathy                  | Increased                    |
|             | [51]      | PBMC                         | qPCR              | Hypertensive heart disease                | Increased                    |
|             | [52]      | Plasma                       | qPCR              | Non-ST elevation myocardial infarction (NSTEMI) | Increased | |
|             | [53]      | Plasma                       | qPCR              | Acute coronary syndrome                   | Increased                    |
|             | [54]      | Right arterial appendage biopsies + Plasma | qPCR | Atrial fibrillation                       | Increased | |
|             | [55]      | Myocardial tissue            | qPCR + miRNA array| Atrial fibrillation                      | Increased                    |
|             | [56]      | Myocardial tissue            | qPCR              | Heart failure                             | Decreased                    |
|             | [57]      | Serum                        | qPCR              | Heart failure                             | Decreased                    |
|             | [58]      | Plasma                       | qPCR              | Acute heart failure                       | Decreased                    |
| miR-17-5p   | [59]      | Plasma                       | qPCR              | Acute coronary syndrome                   | Increased                    |
|             | [60]      | Plasma                       | dPCR              | Coronary artery disease                   | Increased                    |
|             | [61]      | Plasma                       | qPCR              | Heart failure                             | Decreased                    |
|             | [62]      | Plasma                       | qPCR              | Hypertrophic cardiomyopathy               | Increased                    |
|             | [63]      | Whole blood                  | qPCR              | Bicuspid aortic valve disorder            | Decreased                    |
| miR-19a     | [64]      | Lung tissue                  | microarray        | Pulmonary arterial hypertension            | Increased                    |
|             | [65]      | Serum                        | qPCR              | Acute coronary syndrome                   | Increased                    |
|             | [66]      | Serum                        | microarray        | Atherosclerosis                           | Increased                    |
| miR-29a-3p  | [67]      | Ascending aorta tissue       | qPCR              | Bicuspid aortic valve disorders           | Decreased                    |
|             | [68]      | Serum                        | qPCR              | Hypertrophic cardiomyopathy               | Increased                    |
|             | [69]      | Serum                        | qPCR              | Hypertrophic cardiomyopathy               | Increased                    |
|             | [70]      | Plasma                       | qPCR              | Hypertrophic cardiomyopathy               | Increased                    |
|             | [71]      | Plasma                       | qPCR              | Coronary heart disease                    | Increased                    |
|             | [72]      | Cardiac valve tissue         | qPCR              | Valvular heart disease                    | Decreased                    |
|             | [73]      | Plasma                       | qPCR              | Cardiac fibrosis                          | Increased                    |
|             | [74]      | Plasma                       | qPCR              | Left ventricular remodelling              | Increased                    |
|             | [75]      | Plasma                       | qPCR              | Pulmonary arterial hypertension           | Increased                    |
| miRNA    | Reference | Sample Type                | Evaluation Method      | Cardiovascular condition                  | Expression Change to controls |
|----------|-----------|----------------------------|------------------------|-------------------------------------------|------------------------------|
| miR-34a-5p | [76]      | Plasma                     | qPCR                   | Chronic heart disease                     | Increased                   |
|          | [77]      | Whole blood                | qPCR                   | Cardiac aging                             | Increased                   |
|          | [78]      | Plasma                     | qPCR                   | Left ventricular (LV) remodelling         | Increased                   |
|          | [79]      | Plasma                     | qPCR                   | Left ventricular dysfunction              | Increased                   |
|          | [80]      | Plasma                     | qPCR                   | Heart failure                             | Increased                   |
|          | [81]      | Serum                      | qPCR                   | Acute myocardial infarction               | Increased                   |
|          | [82]      | Serum                      | qPCR                   | Arterial fibrillation                     | Increased                   |
| miR-122-5p | [83]      | Serum                      | qPCR                   | Coronary artery disease                   | Increased                   |
|          | [84]      | Plasma                     | microarray + qPCR      | Acute coronary syndrome                   | Increased                   |
|          | [85]      | Plasma                     | qPCR                   | Cardiogenic shock                         | Increased                   |
|          | [86]      | Whole blood                | qPCR                   | Cardiogenic shock                         | Increased                   |
|          | [87]      | Plasma                     | qPCR                   | Ventricular fibrillation sudden cardiac arrest | Increased                   |
|          | [88]      | Plasma                     | qPCR                   | Chronic systolic heart failure            | Increased                   |
|          | [89]      | Plasma                     | microarray             | Aortic valve dysfunction                  | Decreased                   |
|          | [90]      | Ascending aorta tissue + plasma | qPCR           | Bicuspid aortic valve disease             | Decreased                   |
|          | [91]      | Myocardial tissue          | NGS + qPCR             | Arrhythmogenic cardiomyopathy             | Increased                   |
|          | [92]      | Serum                      | qPCR                   | Acute myocardial infarction               | Increased                   |
|          | [93]      | Serum                      | microarray             | Congestive heart failure                  | Increased                   |
| miR-130a | [59]      | Plasma                     | qPCR                   | Acute coronary syndrome                   | Increased                   |
|          | [94]      | Plasma                     | qPCR                   | Peripartum cardiomyopathy                 | Increased                   |
|          | [95]      | Whole blood                | microarray             | Pulmonary hypertension                    | Increased                   |
|          | [96]      | Plasma                     | qPCR                   | Coronary heart disease                    | Decreased                   |
|          | [89]      | Plasma                     | microarray             | Aortic valve dysfunction                  | Increased                   |
| miR-199a-3p | [97]     | Plasma                     | qPCR                   | Acute heart failure                       | Decreased                   |
|          | [98]      | Right arterial appendage biopsies | qPCR           | Postoperative atrial fibrillation          | Decreased                   |
|          | [99]      | Plasma                     | qPCR                   | Coronary heart disease                    | Decreased                   |
|          | [100]     | Right arterial appendage biopsies | qPCR           | Coronary heart disease                    | Decreased                   |
|          | [101]     | Plasma                     | qPCR                   | Stable coronary artery disease             | Decreased                   |
|          | [102]     | Plasma                     | qPCR                   | Peripheral arterial disease               | Decreased                   |
|          | [103]     | Plasma                     | microarray + qPCR      | Atrial fibrillation in HFrEF patients     | Increased                   |
|          | [104]     | Plasma                     | NGS                    | Acute myocardial infarction               | Increased                   |
| miR-378  | [105]     | Plasma                     | qPCR                   | Coronary heart disease                    | Decreased                   |
|          | [106]     | Whole blood                | microarray + qPCR      | Coronary artery disease                   | Decreased                   |
hypertrophy (TASH) [48], the congenital heart malformation Tetralogy of Fallot [49], stress-related Takotsubo cardiomyopathy [50], hypertensive heart disease [51], geriatric patients with acute non-ST elevation myocardial infarction (NSTEMI) [52], acute coronary syndrome [53] and post-operative atrial fibrillation of coronary artery bypass patients [54, 55]. In contrast to upregulation of miR-1 in all of these cardiovascular conditions, consistent downregulation of miR-1 has been noted in heart failure [56–58], which indicates a diversity of roles of this microRNA in the process of cardiac injury.

**Hsa-miR-17**

miR-17 forms part of a cluster of miRNAs’ (including miR-17-5p and -3p, miR-18a, miR-19a and b, miR-20a and miR-92a) with varied and significant roles in cancer and aging [126]. miR-17 has been shown to inhibit the transforming growth factor β (TGF-β) pathway which

| miRNA  | Reference | Sample Type | Evaluation Method | Cardiovascular condition | Expression Change to controls |
|--------|-----------|-------------|-------------------|--------------------------|-------------------------------|
| miR-423 | [107]     | Plasma      | qPCR              | Acute myocardial infarction | Increased                    |
|        | [108]     | Plasma      | qPCR              | Dilated cardiomyopathy    | Increased                    |
|        | [109]     | Plasma      | microarray        | Heart failure             | Increased                    |
|        | [58]      | Plasma      | qPCR              | Acute heart failure       | Decreased                    |
|        | [110]     | Plasma      | qPCR              | Acute heart failure       | Increased                    |
|        | [111]     | Serum       | qPCR              | Coronary artery disease   | Decreased                    |
|        | [38]      | Plasma      | NGS               | Acute myocardial infarction | Increased                    |
|        | [112]     | Plasma      | qPCR              | Acute myocardial infarction | Increased                    |
|        | [113]     | Plasma      | qPCR              | Cardiogenic shock         | Increased                    |
|        | [114]     | Plasma      | qPCR              | Left ventricular remodelling | Increased                    |
|        | [115]     | Serum       | qPCR              | Left ventricular remodelling | Increased                    |
|        | [116]     | Whole blood | microarray + qPCR | Transposition of the great arteries | Increased                    |
|        | [117]     | Serum       | qPCR              | Heart failure             | Increased                    |
|        | [80]      | Plasma      | qPCR              | Heart failure             | Increased                    |
|        | [38]      | Plasma      | NGS               | Acute myocardial infarction | Increased                    |
|        | [41]      | Plasma      | qPCR              | Acute myocardial infarction | Increased                    |
|        | [118]     | Plasma      | qPCR              | Acute myocardial infarction | Increased                    |
|        | [119]     | Whole blood | qPCR              | Acute myocardial infarction | Increased                    |
|        | [120]     | Serum       | dPCR+qPCR         | Stable coronary artery disease | Increased                    |
|        | [40]      | Plasma      | qPCR              | Acute coronary syndrome    | Increased                    |
|        | [121]     | Plasma      | qPCR              | Acute coronary syndrome    | Increased                    |
|        | [115]     | Serum       | qPCR              | ST-segment-elevation myocardial infarction (STEMI) | Increased                    |
|        | [52]      | Plasma      | qPCR              | Non-ST elevation myocardial infarction (NSTEMI) | Increased                    |
|        | [122]     | Endomyocardial biopsies | qPCR | Dilated cardiomyopathy | Increased                    |
|        | [123]     | PBMC        | qPCR              | Heart failure with preserved ejection fraction (HFrEF) | Increased                    |
|        | [42]      | FFPE myocardial tissue | qPCR | Sudden cardiac death | Increased                    |
|        | [83]      | Serum       | qPCR              | Unstable coronary artery disease | Increased                    |

PBMC: Peripheral blood mononuclear cells, FFPE: Formalin-fixed paraffin-embedded tissue, NGS: Next generation sequencing, qPCR: Quantitative polymerase chain reaction, dPCR: Digital polymerase chain reaction
results in instability of atherosclerotic plaques in acute coronary syndrome [59] and coronary artery disease [60]. Another target of miR-17 is the connective tissue growth factor (CTGF) and thrombospondin-1 which affects myocardial fibrosis and significant expression of miR-17 has been linked to heart failure [61] and hypertrophic cardiomyopathy [62]. Increasing the activity of matrix metalloproteinases (MMPs) by miR-17 leads to breakdown of the extracellular matrix (ECM) which is a key factor in bicuspid aortic valve disorder [63].

Hsa‑miR‑19a
miR-19a is strongly associated with several cancer types and even functions as an oncomir within the AKT-mTOR signalling pathway via silencing of the PTEN tumor suppressor gene [126]. Upregulation of miR-19a has been associated with reducing the levels of the bone morphogenetic protein receptor type II (BMPR2) linked to pulmonary arterial hypertension [64]. The HMG-Box Transcription Factor 1 (HBP-1) gene is a known target for miR-19a which leads to an increase in macrophage migration inhibiting factor (MIF) that links miR-19a overexpression to both acute coronary syndrome [65] and atherosclerosis [66].

Hsa‑miR‑29a
miR-29a is also part of a family of microRNAs which target a group of functionally related genes involved in apoptosis (Tcd1, McI1, p85a, CDC42, YY1, CDK6), cell differentiation (YY1, HDAC4), regulation of the extracellular matrix proteins (Collegen I, III, IV), LAMC1, FBNI, ELN, MMP2, ITGB1) and immune responses (B7-H3, Interferon-γ) [127]. In cardiovascular diseases it has been linked to bicuspid aortic valve disorders [67], hypertrophic cardiomyopathy [68, 69, 62], coronary heart disease [70, 71], valvular heart disease [72], cardiac fibrosis [73], left ventricular remodelling [74] and pulmonary arterial hypertension [75]. The levels of circulating miR-29a are also thought to be linked to haemolysis of blood cells linked to certain cardiac pathologies rather than directly secreted only from the cardiomyocyte cells [128].

Hsa‑mir‑34a
The miR-34 family has a variety of functions relating to cancer, particularly in the p53 tumor suppressor pathway [129] and it has been implicated in the processes of cardiac apoptosis, telomere attrition, DNA damage and inflammatory responses [130]. miR-34a influences lipid metabolism by inhibiting the Sirtuin 1 (SIRT1) pathway as well as stimulating pro-inflammatory cytokines such as IL-1b, IL-7A CRP and TNF-α which are strongly associated with cardiovascular diseases [76]. Links between miR-34a and several cardiovascular disorders have been well established including; chronic heart disease [76], cardiac aging [77], left ventricular (LV) remodelling [78], LV dysfunction [79], heart failure [80], acute myocardial infarction [81] and arterial fibrillation [82].

Hsa‑mir‑122‑5p
miR-122-5p is highly expressed within the liver where it is involved in lipid metabolism and hepatocyte homeostasis [131]. This may be a factor in the associations with lipid-related conditions such as coronary artery disease [83] and acute coronary syndrome [84]. Damage to hepatocytes was concluded to be the source of miR-122 from hypoperfusion resulting in significant expression during cardiogenic shock [85, 86], ventricular fibrillation sudden cardiac arrest [87] and chronic systolic heart failure [88]. miR-122 has been implicated in aortic valve dysfunctions through its mediating of tissue fibrosis and the
extracellular matrix via the TGFβRI gene [89, 90]. It has also been associated with arrhythmogenic cardiomyopathy [91], acute myocardial infarction [92] and congestive heart failure [93].

**Hsa-miR-130a**

miR-130a has been associated with apoptosis and angiogenesis. It has been found to be significantly expressed in the conditions of acute coronary syndrome [59] by acting on TNF-α, Toll-like receptors (TLR) and transcription factor NF-kb. The downregulation of the ERBB4 Tyrosine kinase receptor by miR-130 leading to increased left ventricle dilation and hypertrophy was found in the condition of peripartum cardiomyopathy [94]. It has also been linked to pulmonary hypertension [95], coronary heart disease [96] and aortic valve dysfunction [89].

**Hsa-miR-199a**

miR-199a is widely expressed in the myocardium and is highly sensitive to oxygen tension and hypoxia [132]. It has been linked to Sirtuin 1 (SIRT1) which is a cardioprotective protein involved in the regulation of angiogenesis, endothelial function and vascular homeostasis. Down-regulation of miR-199a has been noted in acute heart failure patients [97] and leads to an increase in SIRT1 expression in postoperative atrial fibrillation [98] and coronary heart disease [99–101]. Downregulated miR-199 also increased levels of atherosclerosis-related biomarkers (Angiogenin, Galactin-3 and Neuropilin-1) in heart failure patients with peripheral artery disease [102]. Increased miR-199 has also been associated to atrial fibrillation in HFrEF patients [103] and acute myocardial infarction [104].

**Hsa-miR-378a-3p**

miR-378a has varied functions in metabolism, muscle development, inflammation and angiogenesis [133]. It is highly expressed by cardiomyocytes but evidence for a specific role in response to cardiac damage is still unclear [133]. Significant down-regulation of miR-378 has been noted in both coronary heart disease [105] and coronary artery disease [106].

**Hsa-miR-423**

miR-423 has a functional role in cardiomyocyte apoptosis and has been linked to regulation of transcription factors of the OGT and PA2G4 genes in evidence from animal and in silico models [107]. It is correlated with levels of the cardiomyocyte-secreted hormone NT-proBNP which is used widely as a diagnostic of heart failure [108, 109]. Dysregulation of miR-423 has been found to be highly variable between cardiac disorders and potentially subject to rapid changes. Decreased levels have been linked to poor clinical outcomes in acute heart failure patients [58, 110] and lower risk in coronary artery disease [111]. Whereas, significantly increased miR-423 has been found in many cardiac disorders including acute myocardial infarction [38, 107, 112], cardiogenic shock [113], dilated cardiomyopathy [108], left ventricular remodelling [114, 115], transposition of the great arteries [116] and heart failure [80, 109, 117].

**Hsa-miR-499**

miR-499 is highly expressed in heart muscle and is released directly from the heart myocardium following tissue damage [40]. It has 70 primary mRNA targets involved in the developmental and metabolic pathways including SRY box 6 (Sox6), thyroid hormone receptor associated protein 1 (THRAP1), myocyte enhancer factor 2C (MEF2C), insulin-like growth factor-1 (IGF-1), pyruvate dehydrogenase subunit X (PDHX) and mediator complex subunit 13 (MED13) [134]. miR-499 also regulates the kinase/phosphatase pathways, βMHC (myosin heavy chain) isoform switching, phosphorylation of the signalling proteins HSP90β and PP1α, mitogen-activated protein kinase (MAPK) cascades, mRNA transcription via Hipk1 and Hipk2 regulation, Ca²⁺ transport and cell survival [134]. Increased expression of miR-499 has been found in acute myocardial infarction [38, 41, 118, 119], stable coronary artery disease [120], acute coronary syndrome [40, 121], ST-segment-elevation myocardial infarction (STEMI) [115], non-ST elevation myocardial infarction (NSTEMI) [52], dilated cardiomyopathy [122], heart failure with preserved ejection fraction (HFrEF) [123], sudden cardiac death [42] and unstable coronary artery disease [83].

**Hsa-miR-885-5p**

Recently identified as a regulator of cardiomyocyte apoptosis in human cardiomyocytes through inhibition of the genes PTEN, BCL2L11 and modulation of the AKT/mTOR signalling pathway [135]. miR-885 is also implicated in metastasis of certain cancers and as an indicator of toxic liver damage [136, 137] but no relevant clinical studies supporting the association of this microRNA with cardiovascular diseases were found.

**Hsa-miR-1273 g-3p**

miR-1273 g has been linked to breast cancer [138, 139] and radiation treatments of cancer [140]. However, no clinical studies have reported a link with cardiovascular diseases and therefore, this microRNA is not currently considered informative for cardiotoxicity in breast cancer patients.
Hsa-miR-4638-3p
No relevant clinical studies were identified to confirm the association of this microRNA with cardiovascular diseases.

Discussion
Based on a systematic review of existing literature, 29 miRNA markers were identified for the investigation of chemotherapy induced cardiotoxicity (CIC) in breast cancer patients [28–35] (Table 1). However, a lack of replication of results amongst miRNA studies is highlighted as a major limitation of identifying informative miRNA markers, with many studies producing conflicting results or not supporting previously observed significant changes in miRNA expression. Therefore, for this review a strategy of grouping miRNAs by evidence of the type of replication was adopted whereby miRNAs were considered informative if they showed significant changes in expression in one or more studies and if they had been independently replicated but found to be non-significant in another study (Table 1, Sections A & B). miRNAs that have been found to be non-significant in one or more independently replicated studies were rejected (Table 1, Section C), as were miRNAs which were found to have conflicting directions of expression change in independently replicated studies (Table 1, Section D). The 14 shortlisted miRNAs were further examined in the literature for clinical studies of patients with cardiovascular diseases (Table 3) to identify corresponding cardiac conditions where these miRNAs have been found to have a significant change in expression. The direction of expression changes seen in these microRNAs were also replicated in a number of other cardiovascular diseases which confirms their utility as biomarkers of cardiac damage similar to that expected from cardiotoxicity (cardiomyocyte apoptosis, hypertrophy and fibrosis). However, three miRNAs were rejected for a lack of supporting evidence as no relevant publications in any cardiovascular conditions have reported findings for these markers. Therefore, the remaining 11 miRNAs (miR-1, 17, 19a, 29a, 34a, 122, 130a, 199a, 378a, 423 and 499) were concluded to be most suitable for the detection of cardiac damage resulting from exposure to chemotherapy agents.

Many of the miRNAs reported in the reviewed cardiotoxicity studies showed no significant changes between symptomatic and control groups which could indicate that either these markers were not activated within the pathway of cardiotoxic damage or that they may have been expressed at an earlier or later time point. The expression of miRNAs is known to change rapidly in some cardiomyopathies [74] and few of the studies included multiple sampling points. The majority of the clinical studies cited measured miRNAs immediately post-treatment or within 6 months of the end of treatment and only two studies took samples during the chemotherapy treatment period [28, 31]. The temporal variation in circulating microRNA expression may not necessarily be related to cardiotoxicity but to other comorbidities, functional pathways or patient-related factors [141]. Expression changes of miRNAs related to skeletal muscle and the cardiovascular system have been noted to be influenced by exercise for up to 24 hrs [142]. Dietary factors such as alcohol [143] and saturated fatty acids [144] can also influence miRNAs, in addition to the potential for homologous xenomiRs of plant [145] and animal [146] origin that can persist through the human digestive system. miRNA data is inherently noisy due to these exogenous factors which when combined with variability and uncertainties introduced by the methods of sample processing and analysis [147], make the use of such data very difficult and open to errors.

A major limitation of the studies listed in Table 1 is the small number of patients in the groups showing cardiotoxicity, between 7 and 20 subjects (Table 2), who were primarily classified by reduced LVEF (Left Ventricular Ejection Fraction) or elevated Troponin levels. This is reflected in the lack of repeatability between studies for the same microRNAs resulting in no significant changes in expression detected and a reduced statistical power for detecting dysregulation [148]. Small sample size reduces both the probability of detecting an effect and also that a statistically significant result reflects a true effect [149]. This is driven by the standard error of the measurements for miRNAs, the source of which may be interaction of a specific miRNA with different mRNA and gene pathways. Thus, it is essential to keep in mind that some miRNAs may suffer from a higher standard error, that cannot be adequately quantified or addressed with the small sample sizes found in most of the reviewed studies. Therefore, in addition to collating literature reporting statistically significant miRNA biomarkers associated to cancer treatment induced cardiotoxicity, we also looked at the change in level of expression of the reported miRNA in each group (cardiotoxic vs non-cardiotoxic). We expect true positive effects to replicate across independent studies, not just in terms of being statistically significant, but also in terms of the change of direction in the level of expression (increase versus decrease). Many of the attempted replications although reported as statistically significant in more than one scientific publication, in fact report opposite directionality in the level of expression in otherwise matching groups. This indicates that the quantification of this miRNA has a higher standard error and, therefore, is more prone to wide variations in measurements in groups of small sizes, resulting in false positive findings. An outcome of this manuscript is that there is
a clear need to assess the standard error of each miRNA in terms of the replicability of measurements within a homogeneous group of patients. This value, along with all other required parameters (expected effect sizes, analytical approach, etc) should then be used to calculate the minimum sample sizes required for any study that considers that specific miRNA as a potential biomarker. Large sample sizes can offset high standard error in miRNAs, although to determine exactly how large these sample sizes need to be requires some assumptions in terms of the expected effect sizes and standard error in miRNA quantification. To address such issues, the co-authors of this manuscript are working through the CardioCare project funded under Horizon2020 to establish a large patient cohort (750 breast cancer patients determined based on statistical power analyses), that explores miRNAs as well as other potential biomarkers of cancer treatment induced cardiotoxicity with results expected in 2024 [150].

Interpretation of the expression of one specific miRNA is difficult due to the potential confounding variables in patients with different characteristics, comorbidities and treatment regimes. Therefore, it is considered essential to apply a panel of several miRNAs linked to a condition of interest so that a profile of expression changes is generated, rather than relying on a single miRNA [151, 152]. Such panels have been developed previously for cardiovascular conditions such as myocardial infarction [153], dilated cardiomyopathy [151] and have been applied for prognostic and diagnostic purposes in other conditions including breast cancer [154], prostate cancer [155] and non-small cell lung cancer [156]. The nature of the chemotherapy agent appears to play a significant role in the expression of miRNAs as different agents elicited responses in different markers. The majority of studies have focused on anthracycline use and cardiotoxicity as this group of drugs are known to cause higher rates of cardiac damage than other chemotherapy agents [5]. Doxorubicin indicated significant changes in miRNA expression whereas, Epirubicin used as a single therapy did not [32]. Epirubicin is commonly used in conjunction with Cyclophosphamide (alkylating agent) and Docetaxel or Paclitaxel (antimicrotubule agents) (termed EC-D or NAC regimes) and these treatments did result in dysregulation of several miRNAs with some differences to Doxorubicin. Only one study reported a significantly differentially expressed miRNA in patients undergoing an EC-D plus Trastuzumab monoclonal antibody therapy [35]. From the results presented here a panel of informative miRNA markers specific to each chemotherapy approach is suggested as shown in Fig. 4. Three miRNA markers; miR-29a, miR-34a and miR-423, are considered as general cardiotoxicity indicators and these should be supplemented by miR-1, miR-499 and miR-122 for patients undergoing a Doxorubicin treatment regime or miR-17, miR-19a, miR-199 and miR-378, for patients undergoing an EC-D regime. Additionally, for patients undergoing a Trastuzumab regime, miR-130a can be utilised. Thus, three panels of seven to eight miRNAs are suggested as the most effective approach to identify chemotherapy induced cardiotoxicity in breast cancer patients. Further research is required to investigate the prognostic

Fig. 4 Panels of most-informative microRNAs for chemotherapy-induced cardiotoxicity in breast cancer patients separated by treatment type: DOX = Doxorubicin, EC-D = Epirubicin + Cyclophosphamide & Docetaxel, NAC = Cyclophosphamide + Epirubicin & Paclitaxel, EC-D + T = Epirubicin + Cyclophosphamide & Docetaxel + Trastuzumab
value of each panel and the precise miRNA responses to each specific chemotherapy regime and prove clinical relevance of these panels.

miRNA modulation holds good promise as a therapeutic strategy to counteract cardiotoxicity induced by anticancer treatments. miRNAs are useful both as biomarkers of cardiotoxicity and for targeted therapy, since they may modulate entire signalling pathways. Unfortunately, many miRNAs modulated by anticancer treatments are also involved in cardiotoxicity. Therefore, the comprehension of the mechanisms elicited by miRNAs and the amelioration of specific delivery in either cardiac or tumor regions, could help to reduce negative side effects.

Conclusion
The current body of evidence reveals that miRNAs can potentially offer clinically relevant information with regards to chemotherapy induced cardiotoxicity. However, many miRNAs reported as associated with these conditions may be the outcome of underpowered studies due to small sample sizes. This has led to poor replication of results between studies and limits the evidence for the application of miRNAs as clinical biomarkers. Through this work, we present a systematic review of relevant miRNA studies and a list of the most informative miRNAs based on independent replication, direction of significant expression change and additional evidence from clinical studies of each miRNA within the wider field of cardiovascular disease. The list of potential miRNA biomarkers to assess cardiotoxicity in cancer care are presented as a panel which can be modified to the therapeutic approach under consideration. We recommend more studies with sufficient statistical power to accurately evaluate the potential use of miRNAs in clinical care. Statistical power needs to be assessed based on empirically quantified parameters for each miRNA considered.

Acknowledgements
Not applicable.

Authors’ contributions
Concept and design of manuscript: CB, AA, DF, MM. Data collection and analysis: CB, AA, CS, EN, EI. Drafting and editing of manuscript: CB, AA, GK, PV, FT. Expert review and comments: GC, DC, GF, MN, KN, AP, EP, AC. All authors read and approved the final manuscript.

Funding
The study was supported through the EU Horizon 2020 project CARDIOCARE (Grant agreement ID: 945175).

Availability of data and materials
Not applicable.

Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Stremble Ventures Ltd, 59 Christaki Kranou, 4042 Limassol, Cyprus. 2University of Ioannina, 45110 Ioannina, Greece. 3Bank of Cyprus Oncology Centre, 32 Acropolis Avenue, 2006 Strovolos, Nicosia, Cyprus. 4European Institute of Oncology, IRCCS and University of Milan, Milan, Italy. 5National and Kapodistrian University of Athens, Athens University Hospital Attikon, Athens, Greece. 62nd Department of Cardiology, Faculty of Medicine, School of Health Sciences, University of Ioannina, and University Hospital of Ioannina, Ioannina, Greece. 7Department of Oncology-Pathology, Karolinska Institutet and University Hospital, Stockholm, Sweden.

Received: 13 May 2022   Accepted: 2 August 2022

Published online: 07 September 2022

References
1. McGowan JV, et al. Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Ther. 2017;31:63–79.
2. Gonciar D, Mocan L, Zilbaut A, Mocan T, Agoston-Coldea L. Cardiotoxicity in HER2-positive breast cancer patients. Heart Fail Rev. 2021;26:919–35.
3. Nicolazzi MA, et al. Anthracycline and trastuzumab-induced cardiotoxicity in breast cancer. Eur Rev Med Pharmacol Sci. 2018;22:175–85.
4. Stolzefus KC, et al. Fatal heart disease among cancer patients. Nat Commun. 2020;11:2011.
5. Zamarano JL, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:2768–801.
6. Cardinale D, Biasillo G, Cipolla CM. Curing Cancer, saving the heart: a challenge that Cardioncology should not miss. Curr Cardiol Rep. 2016;18:51.
7. Xiao H, et al. Advances in biomarkers for detecting early Cancer treatment-related cardiac dysfunction. Front Cardiovasc Med. 2021;8:753313.
8. Pudil R, et al. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the cardioncology study Group of the Heart Failure Association and the cardioncology Council of the European Society of Cardiology. Eur J Heart Fail. 2020;22:1966–83.
9. Cardinale D, et al. Anthracycline-induced cardiotoxicity: a multicenter randomised trial comparing two strategies for guiding prevention with enalapril: the international CardioOncology society-one trial. Eur J Cancer. 2018;94:126–37.
10. Curigliano G, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31:171–90.
11. Yang X, et al. Potential Gene Association studies of chemotherapy-induced cardiotoxicity: a systematic review and Meta-analysis. Front Cardiovasc Med. 2021;8:651269.
12. Aminkeung F, et al. Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity. Br J Clin Pharmacol. 2016;82:683–95.
13. Norton N, Weil RM, Advani PP. Inter-individual variation and Cardioprotection in anthracycline-induced heart failure. J Clin Med. 2021;10:4079.
14. Chatterjee S, Gupta SK, Bar C, Thum T. Noncoding RNAs: potential regulators in cardioncology. Am J Physiol Heart Circ Physiol. 2019;316:H160–8.
15. Romaine SPR, Tomaszewski M, Condorelli G, Samani NJ. MicroRNAs in cardiovascular disease: an introduction for clinicians. Heart. 2015;101:921–8.
16. Mott JL, Mohr AM. Overview of MicroRNA biology. Semin Liver Dis. 2015;35:3–13.
17. Chevillet JR, Lee I, Briggs HA, He Y, Wang K. Issues and prospects of microRNA-based biomarkers in blood and other body fluids. Molecules. 2014;19:6080–105.
18. Ambros V, et al. A uniform system for microRNA annotation. RNA. 2003;9:277–9.
19. Tomassello L, Distefano R, Nigita G, Croce CM. The MicroRNA family gets wider: the IsomiR classification and role. Front Cell Dev Biol. 2021;9:668648.
20. O'Brien J, Hayder H, Zayed Y, Peng C. Overview of MicroRNA biology, mechanisms of actions, and circulation. Front Endocrinol. 2018;9:402.
21. de Freitas RCC, Hirata RDC, Hirata MH, Aikawa E. Circulating extracellular vesicles as biomarkers and drug delivery vehicles in cardiovascular diseases. Mol Biologies. 2021;11:388.
22. Pritchard CC, et al. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev Res (Phila). 2012;5:492–7.
23. Zhang J, et al. Exosomal and Exosomal MicroRNA: trafficking, sorting, and function. Genomics Proteomics Bioinformatics. 2015;13:17–24.
24. Cheng HH, et al. Plasma processing conditions substantially influence circulating microRNA biomarker levels. Plos One. 2013;8:e64795.
25. Condrat CE, et al. miRNAs as biomarkers in disease: latest findings regarding their role in diagnosis and prognosis. Cells. 2020;9:276.
26. Martinez-Dominguez MV, et al. Current technologies for RNA-directed liquid diagnostics. Cancers (Basel). 2021;13:5060.
27. Page MJ, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
28. Frères P, et al. Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients. BMC Cancer. 2018;18:102.
29. Zhu Z, Li X, Dong H, Ke S, Zheng W-H. Let-7f and miRNA-126 correlate with decreased cardiotoxicity risk in triple-negative breast cancer patients who underwent neoadjuvant chemotherapy. Int J Clin Exp Pathol. 2018;11:4987–95.
30. Qin X, Chang F, Wang Z, Jiang W. Correlation of circulating proangiogenic miRNAs with cardiotoxicity induced by epirubicin/cyclophosphamide followed by docetaxel in patients with breast cancer. Cancer Biomark. 2018;23:473–84.
31. Rigaud VO-C, et al. Circulating miR-1 as a potential biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients. OncoTarget. 2017;8:86994–7002.
32. Giovffe S, et al. Circulating MicroRNAs as potential predictors of anthracycline-induced troponin elevation in breast Cancer patients: diverging effects of doxorubicin and Epirubicin. J Clin Med. 2020;9:E1418.
33. Lakhanvi HV, et al. Detecting early onset of anthracyclines-induced cardiotoxicity using a novel panel of biomarkers in west-Virginian population with breast cancer. Sci Rep. 2021;11:7954.
34. Yadi W, et al. Bioinformatic analysis of peripheral blood miRNA of breast cancer patients in relation with anthracycline cardiotoxicity. BMC Cardiovasc Disord. 2020:20:43.
35. Feng Q, et al. MicroRNA-130a increases and predicts cardiotoxicity during adjuvant chemotherapy in human epidermal growth factor Receptor-2-positive breast Cancer. J Breast Cancer. 2021;4:153–63.
36. Su T, Shao X, Zhang X, Yang C, Shao X. Value of circulating miRNA-1 detected within 3 h after the onset of acute chest pain in the diagnosis and prognosis of acute myocardial infarction. Int J Cardiol. 2020;307:146–51.
37. Zhou X, et al. Urine and serum microRNA-1 as novel biomarkers for myocardial infarction in open-heart surgeries with cardiopulmonary bypass. Plos One. 2013;8:e62245.
38. Crouser ED, et al. Circulating exosomal microRNA expression patterns distinguish cardiac sarcoidosis from myocardial ischemia. Plos One. 2021;16:e0246083.
39. Grabmaier U, et al. Diagnostic and prognostic value of miR-1 and miR-29b on adverse ventricular remodeling after acute myocardial infarction - the SITAGRAMI-miR analysis. Int J Cardiol. 2017;244:30–6.
40. Gidlof O, et al. Circulating cardio-enriched microRNAs are associated with long-term prognosis following myocardial infarction. BMC Cardiovasc Disord. 2013:13:12.
41. D’Alessandra Y, et al. Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur Heart J. 2010;31:2765–73.
42. Pinchi E, et al. miR-1, miR-499 and miR-208 are sensitive markers to diagnose sudden death due to early acute myocardial infarction. J Cell Mol Med. 2019;23:6005–16.
43. Coelho-Lima J, et al. Kinetics analysis of circulating MicroRNAs unveils markers of failed myocardial reperfusion. Clin Chem. 2020;66:247–56.
44. Marketou M, et al. Peripheral blood MicroRNAs as potential biomarkers of myocardial damage in acute viral myocarditis. Genes (Basel). 2021;12(3):420.
45. Thottakara T, et al. A novel miRNA screen identifies miRNA-4454 as a candidate biomarker for ventricular fibrosis in patients with hypertrophic cardiomyopathy. Biomolecules. 2021;11:1718.
46. Li M, et al. MiR-1-3p that correlates with left ventricular function of HCM can serve as a potential target and differentiate HCM from DCM. J Transl Med. 2018;16:161.
47. Sucharov CC, et al. Myocardial microRNAs associated with reverse remodeling in human heart failure. JCI Insight. 2017;2:e89169.
48. Liebetrut C, et al. Release kinetics of circulating muscle-enriched microRNAs in patients undergoing transcatheter aortic valve septal myectomy. J Am Coll Cardiol. 2021;62:992–8.
49. Grunert M, Appelt S, Dunkel I, Berger F, Spering SR. Altered microRNA and target gene expression related to tetralogy of Fallot. Sci Rep. 2019;9:19063.
50. Jaszewska M, et al. A signature of circulating microRNAs differentiates takotsubo cardiomyopathy from acute myocardial infarction. Eur Heart J. 2014;35:999–1006.
51. Kontaraki JE, et al. Hypertrophic and antihypertrophic microRNA levels in peripheral blood mononuclear cells and their relationship to left ventricular hypertrophy in patients with essential hypertension. J Am Soc Hypertens. 2015;9:802–10.
52. Olivié F, et al. Diagnostic potential of circulating miR-499-5p in elderly patients with acute non ST-elevation myocardial infarction. Int J Cardiol. 2013;167:531–6.
53. Widner C, et al. Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. J Mol Cell Cardiol. 2011;51:872–5.
54. Tsoporis JN, et al. Increased right atrial appendage apoptosis is associated with differential regulation of candidate MicroRNAs 1 and 133A in patients who developed atrial fibrillation after cardiac surgery. J Mol Cell Cardiol. 2018;121:25–32.
55. Slagsvold KH, et al. Comparison of left versus right atrial myocardium for biomarkers of myocardial damage in acute viral myocarditis. Genes (Basel). 2013;167:531–6.
56. Sygitowicz G, et al. Circulating microRNAs as potential markers of myocardial damage in open-heart surgeries with cardiopulmonary bypass. Plos One. 2015;10:e0142237.
57. Danowski N, et al. Decreased expression of miR-133a but not of miR-1 is associated with signs of heart failure in patients undergoing coronary bypass surgery. Cardiology. 2013;125:125–30.
58. Svitojcic G, et al. Circulating microribonucleic acids miR-1, miR-21 and miR-208a in patients with symptomatic heart failure: preliminary results. Arch Cardiovasc Dis. 2015;108:634–42.
59. Serrone M-F, et al. Circulating microRNAs and outcome in patients with heart failure. Plos One. 2015;10:e0142237.
60. Barracough JY, et al. A MicroRNA signature in acute coronary syndrome patients and modulation by colchicine. J Cardiovasc Pharmacol Ther. 2020;25:444–55.
61. Zhelankin AV, et al. Circulating extracellular miRNA analysis in patients with stable CAD and acute coronary syndromes. Mol Biologies. 2021;11:97:962.
62. Shah RV, et al. Associations of circulating extracellular RNAs with myocardial remodeling and heart failure. JAMA Cardiol. 2018;3:871–6.
63. Fang L, et al. Circulating microRNAs as biomarkers for diffuse myocardial fibrosis in patients with hypertrophic cardiomyopathy. J Transl Med. 2015;13:314.
63. Girdauskas E, et al. Evaluation of microribonucleic acids as potential biomarkers in the bicuspid aortic valve-associated aortopathy. Interact Cardiovasc Thorac Surg. 2018;27:60–6.

64. Chen W, Li S. Circulating microRNA as a novel biomarker for pulmonary arterial hypertension due to congenital heart disease. Pediatr Cardiol. 2017;38:86–94.

65. Karakas M, et al. Circulating microRNAs strongly predict cardiovascular death in patients with coronary artery disease-results from the large AtheroGene study. Eur Heart J. 2017;38:516–23.

66. Chen H, Li J, Liu S, Gu L, Zhou X. MicroRNA-19a promotes vascular inflammation and foam cell formation by targeting HBP-1 in atherogenesis. Sci Rep. 2017;7:12089.

67. Haunschild J, et al. Bicuspid aortic valve patients show specific epigenetic tissue signature increasing extracellular matrix destruction. Interact Cardiovasc Thorac Surg. 2019;29:937–43.

68. Derda AA, et al. Blood-based microRNA signatures differentiate various forms of cardiac hypertrophy. Int J Cardiol. 2015;195:15–22.

69. Sonové MR, et al. Circulating levels of MicroRNAs in hypertrophic cardiomyopathy: the relationship with left ventricular hypertrophy, left atrial dilation and ventricular depolarisation-repolarisation parameters. Heart Lung Circ. 2022;31:199–206.

70. Silverman MG, et al. Circulating microRNAs and risk of sudden death in patients with coronary heart disease. JACC Clin Electrophysiol. 2020;6:70–9.

71. Liu C-Z, Zhong Q, Huang Y-Q. Elevated plasma miR-29a levels are associated with increased carotid intima-media thickness in atherosclerosis patients. Tohoku J Exp Med. 2017;241:183–8.

72. Jan MI, et al. Interplay of mitochondria apoptosis regulatory factors and microRNAs in valvular heart disease. Arch Biochem Biophys. 2017;633:50–7.

73. Roncarati R, et al. Circulating miR-29a, among other up-regulated MicroRNAs, is the only biomarker for both hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2014;63:920–7.

74. Zile MR, et al. Relationship between the temporal profile of plasma microRNA and left ventricular remodeling in patients after myocardial infarction. Circ Cardiovasc Genet. 2011;4:614–9.

75. Chouvarine P, et al. Trans-right-ventricle and Transpulmonary MicroRNA gradients in human pulmonary arterial hypertension. Pediatr Crit Care Med. 2020;21:1340–9.

76. Li H, et al. MicroRNA-34a in coronary heart disease: correlation with disease risk, blood lipid, stenosis degree, inflammatory cytokines, and cell adhesion molecules. J Clin Lab Anal. 2022;36:e24138.

77. Seeger T, et al. Immunosenescence-associated microRNAs in age and heart failure. Eur J Heart Fail. 2013;15:385–93.

78. Lv P, et al. Circulating miR-208b and miR-34a are associated with left ventricular remodeling after acute myocardial infarction. Int J Mol Sci. 2014;15:5774–88.

79. Florijn BW, et al. Sex-specific microRNAs in women with diabetes and left ventricular diastolic dysfunction or HfPEF associate with microvascular injury. Sci Rep. 2020;10:13945.

80. De Rosa S, et al. Transcoronary concentration gradients of circulating microRNAs in heart failure. Eur J Heart Fail. 2018;20:10000–10.

81. Matsumoto S, et al. Circulating p53-responsive microRNAs are predictive indicators of heart failure after acute myocardial infarction. Circ Res. 2013;113:322–6.

82. Wang H, et al. Identification of microRNA biomarkers in serum of patients at different stages of atrial fibrillation. Heart Lung. 2020;49:902–8.

83. Singh S, et al. MiR-223-3p and miR-122-5p as circulating biomarkers for plaque instability. Open Heart. 2020;7(1):e001233.

84. Li X, et al. Plasma miR-22 and miR-3149 potentially novel biomarkers for acute coronary syndrome. Plos One. 2015;10:e0125430.

85. Hänninen M, et al. Association of miR-21-5p, miR-122-5p, and miR-320a-3p with 90-day mortality in cardiogenic shock. Int J Mol Sci. 2020;21:7925.

86. Gijple P, et al. The association between plasma miR-122-5p release pattern at admission and all-cause mortality or shock after out-of-hospital cardiac arrest. Biomarkers. 2019;24:29–35.

87. Wander PL, et al. Circulating microRNAs and sudden cardiac arrest outcomes. Resuscitation. 2016;106:96–101.

88. Stojkovic S, et al. Liver-specific microRNA-122 as prognostic biomarker in patients with chronic systolic heart failure. Int J Cardiol. 2020;303:80–5.

89. Martinez-Micelaño N, Beltrán-Devón R, Baiges I, Faiges M, Alegret JM. Specific circulating microRNA signature of bicuspid aortic valve disease. J Transl Med. 2017;15:76.

90. Pisano C, et al. Medial tunica degeneration of the ascending aortic wall is associated with specific microRNA changes in bicuspid aortic valve disease. Mol Med Rep. 2021;24(6):876.

91. Bueno Manns M, et al. A microRNA expression profile as non-invasive biomarker in a large Arrhythmogenic cardiomyopathy cohort. Int J Mol Sci. 2020;21(4):1536.

92. Cortez-Dias N, et al. Circulating miR-122-5p/miR-133b ratio is a specific early prognostic biomarker in acute myocardial infarction. Circ J. 2016;80:2183–91.

93. Cakmak HA, et al. The prognostic value of circulating microRNAs in heart failure: preliminary results from a genome-wide expression study. J Cardiovasc Med (Hagerstown). 2015;16:431–7.

94. Feyer E, et al. ERBB4 and multiple MicroRNAs that target ERBB4 participate in pregnancy-related cardiomyopathy. Circ Heart Fail. 2021;14:e006898.

95. Wei C, et al. Circulating microRNAs as potential marker for pulmonary hypertension. Plos One. 2013;8:e64596.

96. Jia Q-W, et al. Predictive effects of circulating miR-221, miR-130a and miR-155 for coronary heart disease: a multi-ethnic study in China. Cell Physiol Biochem. 2017;42:808–23.

97. Ovchinnikova ES, et al. Signature of circulating microRNAs in patients with acute heart failure. Eur J Heart Fail. 2016;18:414–23.

98. Yamac AH, et al. Altered expression of microRNA-199a and increased levels of cardiac SIRT1 protein are associated with the occurrence of atrial fibrillation after coronary artery bypass graft surgery. Cardiovasc Pathol. 2016;25:232–6.

99. Su M, et al. Circulating microRNA profiles based on direct S-poly(T) plus assay for detection of coronary heart disease. J Cell Mol Med. 2020;24:5984–97.

100. Yamac AH, et al. MicroRNA-199a is downregulated in patients after coronary artery bypass graft surgery and is associated with increased levels of Sirtuin 1 (SIRT1) protein and major adverse cardiovascular events at 3-year follow-up. Med Sci Monit. 2018;24:6245–54.

101. Jansen F, et al. MicroRNA expression in circulating microvesicles predicts cardiovascular events in patients with coronary artery disease. J Am Heart Assoc. 2014;3:e001249.

102. Vegeger EL, et al. Low circulating microRNA levels in heart failure patients are associated with atherosclerotic disease and cardiovascular-related hospitalizations. Clin Res Cardiol. 2017;106:598–609.

103. Garcia-Elias A, et al. Atrial fibrillation in heart failure is associated with high levels of circulating microRNA-199a-5p and 22-5p and a defective regulation of intracellular calcium and cell-to-cell communication. Int J Mol Sci. 2021;22:19:10377.

104. Zhong Z, Wu H, Zhong W, Zhang Q, Yu Z. Expression profiling and bioinformatics analysis of circulating microRNAs in patients with acute myocardial infarction. J Clin Lab Anal. 2020;34:e23099.

105. Zhang H, Hao J, Sun X, Zhang Y, Wei Q. Circulating pro-angiogenic micro-Ribonucleic acid in patients with coronary heart disease. Interact Cardiovasc Thorac Surg. 2018;27:336–42.

106. Weber M, et al. MicroRNA expression profile in CAD patients and the impact of ACEI/ARB. Cardiol Res Pract. 2011;2011:532915.

107. Rizzaccia B, et al. MiR-423 is differentially expressed in patients with stable and unstable coronary artery disease: a pilot study. Plos One. 2019;14:e0216383.

108. Fan K-L, Zhang H-F, Shen J, Zhang Q, Li X-L. Circulating microRNA levels in Chinese heart failure patients caused by dilated cardiomyopathy. Indian Heart J. 2013;65:12–6.

109. Tijssen AJ, et al. MiR423-5p as a circulating biomarker for heart failure. Circ Res. 2010;106:1035–9.

110. Schneider SIDR, et al. Plasma levels of microRNA-21, -126 and -423-5p after the clinical improvement and are associated with the prognosis of acute heart failure. Mol Med Rep. 2018;17:4736–46.

111. Wang X, et al. Circulating MicroRNA-423-3p improves the prediction of coronary artery disease in a general population - six-year
112. Nabiałek E, et al. Circulating microRNAs (miR-423-5p, miR-208a and miR-1) in acute myocardial infarction and stable coronary heart disease. Minerva Cardioangiol. 2013;61:627–37.

113. Jäntti T, et al. Circulating levels of microRNA 423-5p are associated with 90 day mortality in cardiogenic shock. ESC Heart Fail. 2019;6:98–102.

114. Bauters C, et al. Circulating miR-133a and miR-423-5p fail as biomarkers for left ventricular remodeling after myocardial infarction. J Cardiol. 2013;168:1837–40.

115. Galeano-Otero I, et al. Circulating miR-320a as a predictive biomarker for left ventricular Remodeling in STEMI patients undergoing primary percutaneous coronary intervention. J Clin Med. 2020;9(4):1051.

116. Abu-Halima M, Meese E, Abdul-Khaliq H, Raedle-Hurtn T. MicroRNA-183-3p is a predictor of worsening heart failure in adult patients with transposition of the great arteries and a systemic right ventricle. Front Cardiovasc Med. 2021;8:793364.

117. Goren Y, et al. Serum levels of microRNAs in patients with heart failure. Eur J Heart Fail. 2012;14:147–54.

118. Corsten MF, et al. Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease. Circ Cardiovasc Genet. 2010;3:499–506.

119. Adachi T, et al. Plasma microRNA-499 as a biomarker of acute myocardial infarction. Clin Chem. 2010;56:1183–5.

120. Robinson S, et al. Chip-based digital PCR as a novel detection method for quantifying microRNAs in acute myocardial infarction patients. Acta Pharmacol Sin. 2018;39:1217–27.

121. De Rosa S, et al. Transcoronary concentration gradients of circulating microRNAs. Circulation. 2011;124:1936–44.

122. Satoh M, Minami Y, Takahashi Y, Tabuchi T, Nakamura M. Expression of microRNA-208 is associated with adverse clinical outcomes in human dilated cardiomyopathy. J Card Fail. 2010;16:404–10.

123. Marketou ME, et al. MicroRNAs in peripheral mononuclear cells as potential biomarkers in hypertensive patients with heart failure with preserved ejection fraction. Am J Hypertens. 2018;31:651–6.

124. Safa A, et al. miR-1: a comprehensive review of its role in normal development and diverse disorders. Biomed Pharmacother. 2020;132:110903.

125. Kura B, Kalocayova B, Devaux Y, Bartekova M. Potential clinical implications of miR-1 and miR-21 in heart disease and Cardioprotection. Int J Mol Sci. 2020;21:700.

126. Grillari J, Hackl M, Grillari-Voglauer R. miR-17–92 cluster: ups and downs in cancer and aging. Bioenergontology. 2010;11:501–6.

127. Kriegel AJ, Liu Y, Fang Y, Ding X, Liang M. The miR-29 family: genomics, gene expression. J Cell Physiol. 2012;227:237–44.

128. Netelos D, et al. Elevated plasma levels of miR-29a are associated with hemolysis in patients with hypertrophic cardiomyopathy. Clin Chim Acta. 2017;471:231–6.

129. Zhang L, Liao Y, Tang L, MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer. J Exp Clin Cancer Res. 2019;38:53.

130. Li N, Wang K, Li P-F. MicroRNA-34 family and its role in cardiovascular disease. Crit Rev Eukaryot Gene Expr. 2015;25:293–7.

131. Willeit P, Skroblin P, Kiechl S, Fernández-Hernando C, Mayr M. Liver microRNAs: potential mediators and biomarkers for metabolic and cardiovascular disease? Eur Heart J. 2016;37:3260–6.

132. Zhou Y, et al. Downregulation of microRNA-199a-5p protects cardiomyocytes in cyanotic congenital heart disease by attenuating endoplasmic reticulum stress. Mol Med Rep. 2017;16:2992–3000.

133. Krist B, Floczczuk Y, Pietraszek-Gremplewicz K, Józkowicz A, Dukal J. The role of miR-378a in metabolism, angiogenesis, and muscle biology. Int J Endocrinol. 2015;2015:e281756.

134. Matkovich SJ, Hu Y, Eschenbacher WH, Dorn LE, Dorn GW. Direct and indirect involvement of microRNA-499 in clinical and experimental cardiomyopathy. Circ Res. 2012;111:521–31.

135. Meng X, Mei L, Zhao C, Chen W, Zhang N. miR-885 mediated cardioprotection against hypoxia/reoxygenation-induced apoptosis in human cardiomyocytes via inhibition of PTEN and BCL2L11 and modulation of AKT/mTOR signaling. J Cell Physiol. 2020;235:8048–57.

136. Vliegenthart ADB, et al. Comprehensive microRNA profiling in acetaminophen toxicity identifies novel circulating biomarkers for human liver and kidney injury. Sci Rep. 2015;5:15501.

137. Rivoli L, et al. The effect of renal dysfunction and haemodialysis on circulating liver specific miR-122. Br J Clin Pharmacol. 2017;83:584–92.

138. Fang R, et al. Plasma MicroRNA pair panels as novel biomarkers for detection of early stage breast cancer. Front Physiol. 2018;9:1879.

139. Guo H, et al. Plasma miR-1273g-3p acts as a potential biomarker for early breast ductal Cancer diagnosis. An Acad Bras Cienc. 2020;92:e20181203.

140. Song M, et al. A biomarker panel of radiation-upregulated miRNA as signature for sonizing radiation exposure Life (Basel). 2020;10:E361.

141. Domarńska-Senderowska D, et al. MicroRNA profile and adaptive response to exercise training: a review. Int J Sports Med. 2019;40:227–35.

142. Szabo G, Satishchandran A. MicroRNAs in alcoholic liver disease. Semin Liver Dis. 2015;35:36–42.

143. Yang W-M, Jeong H-J, Park S-Y, Lee W. Induction of miR-29a by saturated fatty acids impairs insulin signaling and glucose uptake through translational repression of IRS-1 in myocytes. FEBS Lett. 2014;588:2170–6.

144. Zhao Q, et al. Evidence for plant-derived xenomiRs based on a large-scale analysis of public small RNA sequencing data from human samples. PloS One. 2018;13:e0187519.

145. Myrzabaeva M, Labeit S, Nyazova R, Akimnyazova A, Ivashchenko A. Identification of bovine miRNAs with the potential to affect human gene expression. Front Genet. 2022;12:705350.

146. Brunet-Vega A, et al. Variability in microRNA recovery from plasma: comparison of five commercial kits. Anal Biochem. 2015;488:28–35.

147. Witwer KW, Halushka MK. Toward the promise of microRNAs – enhancing reproducibility and rigor in microRNA research. RNA Biol. 2016;13:1103–16.

148. Button KS, et al. Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci. 2013;14:365–76.

149. CardioCare Consortium. An Interdisciplinary Approach for the Management of the Elderly Multimorbid Patient with Breast Cancer Therapy Induced Cardiac Toxicity. https://cordis.europa.eu/project/id/945175.

150. Belmonte T, et al. Peripheral microRNA panels to guide the diagnosis of familial cardiomyopathy.Transl Res. 2020;218:1–15.

151. Ren X, et al. A multiplexed ion-exchange membrane-based miRNA (MIX-mir) detection platform for rapid diagnosis of myocardial infarction. Lab Chip. 2021;21:3876–87.

152. Chen L, Bai J, Liu J, Li H, Zheng K. A four-MicroRNA panel in peripheral blood identified as an early biomarker to diagnose acute myocardial infarction. Front Physiol. 2021;12:669590.

153. Kim MW, et al. Multi-miRNA panel of tumor-derived extracellular vesicles as promising diagnostic biomarkers of early-stage breast cancer. Cancer Sci. 2021;112:5078–87.

154. Zhang S, et al. MicroRNA panel in serum reveals novel diagnostic biomarkers for prostate cancer. PeerJ. 2021;9:e11441.

155. Jiang H-G, et al. Four plasma miRNAs act as biomarkers for diagnosis and prognosis of non-small cell lung cancer. Oncol Lett. 2021;22:792.